---
title: High-dose IV ascorbic acid therapy in CCUS patients with TET2 mutations
date: '2024-10-01'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39352751/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20241003195203&v=2.18.0.post9+e462414
source: Blood
description: This was a phase II trial, evaluating the safety/efficacy of high-dose
  IV-ascorbic acid in patients with TET2 mutant CCUS. Eight of 10 patients enrolled
  were eligible for response assessment. At week 20, there were no responses by IWG
  MDS criteria. ...
disable_comments: true
---
This was a phase II trial, evaluating the safety/efficacy of high-dose IV-ascorbic acid in patients with TET2 mutant CCUS. Eight of 10 patients enrolled were eligible for response assessment. At week 20, there were no responses by IWG MDS criteria. ...